PAP

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Retrieved on: 
Monday, April 8, 2024
Diagnosis, The Lancet, Depression, NASW, Partnership, PAP, Psychotherapy, Palliative care, Patient, Research, Gold, American Psychological Association, Standard of care, Anxiety, Cancer, Doctor of Philosophy, Quality of life, Adjustment disorder, Social work, World Health Organization, Clinical trial, Safety, Adjustment, WHO, National Association, DSM-IV codes, APA, FDA, Physician, Health, PBM, Practitioner, Nursing

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that its Australian subsidiary, Psyence Australia Pty Ltd. (“Psyence Australia”), has entered into a partnership with Fluence , a global leader in professional education and training for psychedelic therapy research, and iNGENū CRO Pty Ltd (“iNGENū”), an Australian clinical research organization (CRO), to support an upcoming Phase llb clinical trial.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that its Australian subsidiary, Psyence Australia Pty Ltd. (“Psyence Australia”), has entered into a partnership with Fluence , a global leader in professional education and training for psychedelic therapy research, and iNGENū CRO Pty Ltd (“iNGENū”), an Australian clinical research organization (CRO), to support an upcoming Phase llb clinical trial.
  • According to Lancet Oncology, Adjustment Disorder affects as many as 19% of patients following a life-limiting cancer diagnosis.
  • “The success of the clinical trial relies on rigorous, standardized therapist training designed to achieve the highest standard of patient care,” said Elizabeth Nielson, PhD, Fluence co-founder.
  • Psyence Biomed anticipates enrolling the first subject in the second quarter of 2024 and expects the primary endpoint results to be available in 2025.

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, March 28, 2024
CARE, Sleep apnea, CPAP, Continuous positive airway pressure, Exercise, Environment, VIP, Obstructive sleep apnea, PAP, Shareholder, Webcast, Patient, DME, Sleep, DNA, ODO, AHI, Messenger, Myotherapy, Security (finance), Danaher Corporation, Clinical trial, Therapy, Annual report, Optimism, Dentist, FDA, Food, Pharmaceutical industry

LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults)), today reported financial results and operating highlights for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Importantly, Vivos believes that governmental investigations of unrelated third parties with non-FDA approved products in the sleep apnea treatment space adversely impacted new Vivos case starts and VIP enrollments during 2023.
  • Vivos’ CARE appliances include the flagship DNA oral appliance, the mRNA oral appliance and the mmRNA oral appliance.
  • Since then, we’ve received high levels of inquiries related to our Vivos CARE products that treat OSA in adults.
  • A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations .

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Critical Care Medicine (journal), PAP, Pulmonary alveolar proteinosis, AJRCCM, Abstract, American Journal, Conference, APAP, Diagnosis

The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine (AJRCCM) on May 1, 2024.

Key Points: 
  • The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine (AJRCCM) on May 1, 2024.
  • For more details about the ATS International Conference please visit https://conference.thoracic.org/index.php .
  • Pulmonary Alveolar Proteinosis (PAP): Pathophysiology, Diagnosis, and Management
    Bruce Trapnell, M.D., M.S.
  • will provide an overview of PAP, including the burden of this rare lung disease, the hallmark signs and symptoms of autoimmune PAP (aPAP), the most common form of PAP, and the path to diagnosing aPAP.

Launching its Priority Access Program, Odne Inc. Appoints Joe Werner as Director of Strategic Accounts

Retrieved on: 
Tuesday, April 9, 2024
Growth, Endodontics, PAP, Isthmus, Dental Service Organizations, KOL, Root, AAE, DSO, FDA, Management

GETTYSBURG, Pa., April 9, 2024 /PRNewswire/ -- Jeff Durrbeck, President of Odne Inc., proudly announces the appointment of Joe Werner as Director of Strategic Accounts.

Key Points: 
  • GETTYSBURG, Pa., April 9, 2024 /PRNewswire/ -- Jeff Durrbeck, President of Odne Inc., proudly announces the appointment of Joe Werner as Director of Strategic Accounts.
  • Joe is an essential addition to Odne's education & sales team, especially with the upcoming AAE annual meeting (April 17-20, 2024, Los Angeles), where Odne will launch its Priority Access Program to the endodontic specialist community.
  • The Priority Access Program Associates will form the core of Odne's scientific community, transforming endodontics.
  • The support we receive from our KOLs, partners, and investors and the interest of the endo community in our Priority Access Program, is amazing.

RxLightning and KnippeRx Partner to Streamline Provider Experience and Accelerate Patient Access to Specialty Medications

Retrieved on: 
Monday, March 18, 2024
Health Technology, Data Management, Other Health, Technology, Finance, Practice Management, Pharmaceutical, Managed Care, General Health, Professional Services, Hospitals, Other Technology, Science, Software, Other Science, Health, Ecosystem, Partnership, PAP, Patient, Workflow, Pharmacy, HCP, Nursing

KnippeRx supports a number of PAP initiatives for prominent pharmaceutical manufacturers by offering application management, patient qualification, product dispensing, and patient support.

Key Points: 
  • KnippeRx supports a number of PAP initiatives for prominent pharmaceutical manufacturers by offering application management, patient qualification, product dispensing, and patient support.
  • To start, the two companies launched an embedded, digital enrollment process for over a dozen commonly prescribed medications, with new medications being added in subsequent months.
  • "We are thrilled to partner with RxLightning to transform the specialty medication enrollment experience," said Luke Austin, VP of Patient Support at KnippeRx.
  • To learn more about how KnippeRx PAP Solutions can provide increased efficiency and an improved patient and HCP experience, please contact [email protected] or call 1-85-KNIPPERX (1-855-647-7379).

Fortrea Increases Patient Access Capabilities and Cold Chain Expertise with FortreaRx™ Expansion

Retrieved on: 
Tuesday, February 20, 2024
Senior counsel, PAP, Patient, Pharmacy, Prescription, Pharmaceutical industry

"From our expertise in broad-range disease states to our unwavering commitment to patient assistance, Fortrea excels at delivering timely and impactful solutions to our pharmaceutical sponsors that strive to reduce patient and provider challenges by streamlining enrollment processes and by offering full integration with broader patient support initiatives."

Key Points: 
  • "From our expertise in broad-range disease states to our unwavering commitment to patient assistance, Fortrea excels at delivering timely and impactful solutions to our pharmaceutical sponsors that strive to reduce patient and provider challenges by streamlining enrollment processes and by offering full integration with broader patient support initiatives."
  • FortreaRx’s call center hub of case managers seamlessly manages patient inquiries, counseling and data verification of prescriptions.
  • Fortrea’s patient access team helps patients and providers understand and navigate the complexities of coverage while removing obstacles to get medication to patients.
  • FortreaRx delivers efficient, consultative and cost-effective solutions for manufacturer prescription programs typically resulting in significant yearly savings for patients.

Signifier Medical Technologies Announces Publication of a New Study Exploring Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea

Retrieved on: 
Thursday, March 7, 2024
Health, Medical Devices, Health Technology, Other Health, General Health, Research, Science, Diabetes, Freedom, CPAP, Patient satisfaction, Sleep apnea, Quality of life, Quality-adjusted life year, Treatment, Obstructive sleep apnea, Continuous positive airway pressure, Technology assessment, ICER, Prevalence, Hypertension, Life imprisonment, PAP, Patient, Canadian International Council, NMES, Signified and signifier, DRS, Health technology

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."

Key Points: 
  • Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."
  • Shan Liu, Jan Pietzsch, and a collaborative research team explores the cost-effectiveness of using neuromuscular electrical stimulation (NMES) as a treatment option for patients with mild obstructive sleep apnea (OSA).
  • The results of the exploratory analysis indicated that neuromuscular electrical stimulation may be a cost-effective treatment option for mild OSA compared to no treatment.
  • "We are excited to see the results of this study reinforce the potential of neuromuscular electrical stimulation as a revolutionary treatment option for individuals with mild obstructive sleep apnea," states Mujtaba Chohan, Head of Finance & Chief of Staff at Signifier.

ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea

Retrieved on: 
Monday, February 12, 2024
RMD, SAN, Inhalation, Central sleep apnea, ASV, MyAir, CPAP, Sleep apnea, Culture, Part, Sleep, Obstructive sleep apnea, Exhalation, Respiratory rate, Digital technology, ResMed, ASX, IPAP, PAP, Patient, Ventilation, Software, Pressure, Medical device

AirCurve 11 devices are built on ResMed’s market-leading AirSense 11 platform and enhance the suite of offerings available for healthcare providers and clinicians when determining the best care for sleep apnea patients.

Key Points: 
  • AirCurve 11 devices are built on ResMed’s market-leading AirSense 11 platform and enhance the suite of offerings available for healthcare providers and clinicians when determining the best care for sleep apnea patients.
  • This design allows the device to align more closely with the patient’s natural breathing pattern.
  • myAir3, a patient engagement app that tracks sleep and therapy progress with a daily sleep score, now with support for bilevel patients.
  • AirView, a secure, cloud-based system that helps providers monitor and manage patients’ therapy remotely, enabling an informed pathway to optimal care.

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Retrieved on: 
Tuesday, February 6, 2024
CARE, Policy, AHI, Life, Splint (medicine), Nausea, Myotherapy, UnitedHealth Group, Irritation, Obstructive sleep apnea, Sleep, Nose, Patient, Safety, ResMed, FDA, CPAP, Respironics, PAP, Skin, Food, Mars, Therapy, Vomiting, Dizziness, Continuous positive airway pressure, Death, Headache, Health, Asthma, Pharmaceutical industry

In one market development, members of Vivos’ nationwide network of over 1,850 trained providers are actively treating current and former ResMed and Philips Respironics’ CPAP device users with Vivos CARE oral medical devices.

Key Points: 
  • In one market development, members of Vivos’ nationwide network of over 1,850 trained providers are actively treating current and former ResMed and Philips Respironics’ CPAP device users with Vivos CARE oral medical devices.
  • Vivos-trained providers currently treat failed HGNS cases using Vivos CARE oral medical devices and treatment plans.
  • Vivos believes most OSA patients seeking HGNS implants have high-moderate or severe OSA, leaving Vivos CARE oral medical devices as their only approved oral appliance therapy option.
  • We believe all of these factors create very significant revenue opportunities for us as we continue to spread the word about our product offerings.”

Hologic Announces First and Only FDA-Cleared Digital Cytology System – Genius™ Digital Diagnostics System

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Technology, FDA, Other Health, Health, Women, Oncology, Health Technology, Medical Devices, Artificial Intelligence, Consumer, Multimedia, Cell, Breast cancer, Marie Cassidy, American Cancer Society, 3D, Patient, Laboratory, Artificial intelligence, Cervical cancer, HOLX, Food, PAP, Disease, Acquisition, OB, Woman, Medical device

“Our technologies have had a tremendous impact on decreasing cancer rates in women, and we are incredibly excited by the promise of Genius Digital Diagnostics.

Key Points: 
  • “Our technologies have had a tremendous impact on decreasing cancer rates in women, and we are incredibly excited by the promise of Genius Digital Diagnostics.
  • With the Genius Digital Diagnostics System, the glass slides are digitally imaged and an artificial intelligence algorithm is applied to pinpoint the cells that cytologists and pathologists should review.
  • The Genius Digital Diagnostics System also offers the opportunity for greater collaboration across lab and other healthcare settings.
  • The Genius Digital Diagnostics System is already commercially available in Europe, Australia and New Zealand.